CUE BIOPHARM.INC. DL-,001 Forum: Community User: Support

Hab nur 2500st reicht erstmal

Bin auch drin

Das heißt genau ?

Pasha Sarraf, Director of Cue Biopharma Inc., has reported the acquisition of common shares of Cue Biopharma Inc. The full filing can be accessed through the link below.

Montag 1€🚀🚀🚀🚀🚀

🚀🚀🚀🚀🚀🚀

https://www.stocktitan.net/news/CUE/cue-biopharma-announces-pricing-of-12-0-million-public-sm20yqcgm77k.html

Well.... hat hier jemand ordentlich Gewinn gemacht oder wie siehts bei euch aus?^^

https://www.wallstreet-online.de/nachricht/18467796-cue-biopharma-appoints-industry-veteran-lucinda-warren-as-chief-business-officer

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-host-business-update-call-and-webcast-15

BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.

Sammaaaa! Was ist denn da los? Kennt da schon wer die Zahlen von morgen?

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-announces-strategic-prioritization-autoimmune

https://www.drugtargetreview.com/article/151759/translating-natures-cues-into-breakthrough-immunotherapies/

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-reports-fourth-quarter-and-full-year-2023

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.